Myelofibrosis is an inflammation-driven systemic disease in which cytokines, fibrosis and clonal evolution are inextricably linked. New data show that the control of inflammation has a decisive influence on the course of the disease. Modern therapies that simultaneously modulate JAK signaling pathways, hepcidin regulation and inflammatory networks mark a real paradigm shift.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Bronchiolitis obliterans
Out of shape even without popcorn
- Case study
Guillain-Barré syndrome with a fulminant course
- Suspicion of neuroborreliosis?
Detection of borrelia-specific CSF parameters provides certainty
- The Brain and the Motivation to Eat
Why is it so hard to lose weight?
- Global Recommendation, Swissmedic Approval, and SL Limitation
WHO Guidelines on GLP-1 for Obesity
- Obesity in Children and Adolescents
Gene-Environment Interactions: Polygenic or Monogenic Determinants?
- From Risk Identification to Anti-Inflammatory Intervention
Inflammation as a Treatment Goal in Its Own Right
- H. pylori infection: current study data